碳14和两种强效选择性磷酸二酯酶4型抑制剂的稳定同位素合成。

IF 0.9 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Journal of labelled compounds & radiopharmaceuticals Pub Date : 2023-07-24 DOI:10.1002/jlcr.4054
Bachir Latli, Matt J. Hrapchak, Thomas G. Tampone, Rogelio P. Frutos, Heewon Lee
{"title":"碳14和两种强效选择性磷酸二酯酶4型抑制剂的稳定同位素合成。","authors":"Bachir Latli,&nbsp;Matt J. Hrapchak,&nbsp;Thomas G. Tampone,&nbsp;Rogelio P. Frutos,&nbsp;Heewon Lee","doi":"10.1002/jlcr.4054","DOIUrl":null,"url":null,"abstract":"<p>(<i>R</i>)-2-(4-(Benzo[d]oxazol-2-yl)piperazin-1-yl)-4-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (<b>1</b>) and (<i>R</i>)-2-(4-(4-chlorophenoxy)piperidin-1-yl)-4-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (<b>2</b>) are two potent and selective inhibitors of phosphodiesterase type 4 (PDE4). In this manuscript, we report the detailed synthesis of these two compounds labeled with carbon 14 and with stable isotopes. The core (<i>R</i>)-4-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide is common in both inhibitors. In the radioactive synthesis, the carbon 14 atom was introduced in the benzoxazole moiety using [<sup>14</sup>C]carbon disulfide to obtain <b>[</b><sup><b>14</b></sup><b>C]-1</b> in five steps at a 55% overall yield. [<sup>14</sup>C]Urea was used to incorporate the carbon 14 atom in two steps in the dihydrothieno[3,2-d]pyrimidine intermediate, which was then transformed in four more steps to <b>[</b><sup><b>14</b></sup><b>C]-2</b> at a 30% overall yield. Both compounds were isolated with specific activities higher than 54 mCi/mmol, radio- and chemical-purities higher than 99%, and with excellent enantiomeric excess. In the stable isotope synthesis, [<sup>2</sup>H<sub>8</sub>]piperazine was used to prepare <b>[</b><sup><b>2</b></sup><b>H</b><sub><b>8</b></sub><b>]-1</b> in three steps in 72% overall yield, while [<sup>13</sup>C<sub>6</sub>]phenol was used to prepare <b>[</b><sup><b>13</b></sup><b>C</b><sub><b>6</b></sub><b>]-2</b> in four steps in 18% overall yield.</p>","PeriodicalId":16288,"journal":{"name":"Journal of labelled compounds & radiopharmaceuticals","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Carbon 14 and stable isotope synthesis of two potent and selective phosphodiesterase type 4 inhibitors\",\"authors\":\"Bachir Latli,&nbsp;Matt J. Hrapchak,&nbsp;Thomas G. Tampone,&nbsp;Rogelio P. Frutos,&nbsp;Heewon Lee\",\"doi\":\"10.1002/jlcr.4054\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>(<i>R</i>)-2-(4-(Benzo[d]oxazol-2-yl)piperazin-1-yl)-4-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (<b>1</b>) and (<i>R</i>)-2-(4-(4-chlorophenoxy)piperidin-1-yl)-4-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (<b>2</b>) are two potent and selective inhibitors of phosphodiesterase type 4 (PDE4). In this manuscript, we report the detailed synthesis of these two compounds labeled with carbon 14 and with stable isotopes. The core (<i>R</i>)-4-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide is common in both inhibitors. In the radioactive synthesis, the carbon 14 atom was introduced in the benzoxazole moiety using [<sup>14</sup>C]carbon disulfide to obtain <b>[</b><sup><b>14</b></sup><b>C]-1</b> in five steps at a 55% overall yield. [<sup>14</sup>C]Urea was used to incorporate the carbon 14 atom in two steps in the dihydrothieno[3,2-d]pyrimidine intermediate, which was then transformed in four more steps to <b>[</b><sup><b>14</b></sup><b>C]-2</b> at a 30% overall yield. Both compounds were isolated with specific activities higher than 54 mCi/mmol, radio- and chemical-purities higher than 99%, and with excellent enantiomeric excess. In the stable isotope synthesis, [<sup>2</sup>H<sub>8</sub>]piperazine was used to prepare <b>[</b><sup><b>2</b></sup><b>H</b><sub><b>8</b></sub><b>]-1</b> in three steps in 72% overall yield, while [<sup>13</sup>C<sub>6</sub>]phenol was used to prepare <b>[</b><sup><b>13</b></sup><b>C</b><sub><b>6</b></sub><b>]-2</b> in four steps in 18% overall yield.</p>\",\"PeriodicalId\":16288,\"journal\":{\"name\":\"Journal of labelled compounds & radiopharmaceuticals\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of labelled compounds & radiopharmaceuticals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jlcr.4054\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of labelled compounds & radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jlcr.4054","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

摘要

(R) -2-(4-(苯并[d]恶唑-2-基)哌嗪-1-基)-4-((四氢-2H-吡喃-4-基)氨基)-6,7-二氢噻吩并[3,2-d]嘧啶5-氧化物(1)和(R)-2-(4-氯苯氧基)哌啶-1-基)-4((四羟基-2H-吡烷-4-基)胺基)-6,7--二氢噻吩并[3,3-d]嘧啶-5-氧化物(2)是4型磷酸二酯酶(PDE4)的两种有效且选择性的抑制剂。在这份手稿中,我们报道了这两种用碳14和稳定同位素标记的化合物的详细合成。核心(R)-4-((四氢-2H-吡喃-4-基)氨基)-6,7-二氢噻吩并[3,2-d]嘧啶5-氧化物在这两种抑制剂中都很常见。在放射性合成中,使用[14C]二硫化碳将碳14原子引入苯并恶唑部分,以55%的总产率分五步获得[14C]-1。[14C]尿素用于分两步将碳14原子引入二氢噻吩并[3,2-d]嘧啶中间体中,然后再分四步将其转化为[14C]-2,总产率为30%。这两种化合物都被分离出来,比活性高于54 mCi/mmol,放射性和化学纯度高于99%,并且具有优异的对映体过量。在稳定同位素合成中,[2 H8]哌嗪分三步制备[2 H8]-1,总收率72%,而[13 C6]苯酚分四步制备[13 C6]-2,总收率18%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Carbon 14 and stable isotope synthesis of two potent and selective phosphodiesterase type 4 inhibitors

(R)-2-(4-(Benzo[d]oxazol-2-yl)piperazin-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (1) and (R)-2-(4-(4-chlorophenoxy)piperidin-1-yl)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide (2) are two potent and selective inhibitors of phosphodiesterase type 4 (PDE4). In this manuscript, we report the detailed synthesis of these two compounds labeled with carbon 14 and with stable isotopes. The core (R)-4-((tetrahydro-2H-pyran-4-yl)amino)-6,7-dihydrothieno[3,2-d]pyrimidine 5-oxide is common in both inhibitors. In the radioactive synthesis, the carbon 14 atom was introduced in the benzoxazole moiety using [14C]carbon disulfide to obtain [14C]-1 in five steps at a 55% overall yield. [14C]Urea was used to incorporate the carbon 14 atom in two steps in the dihydrothieno[3,2-d]pyrimidine intermediate, which was then transformed in four more steps to [14C]-2 at a 30% overall yield. Both compounds were isolated with specific activities higher than 54 mCi/mmol, radio- and chemical-purities higher than 99%, and with excellent enantiomeric excess. In the stable isotope synthesis, [2H8]piperazine was used to prepare [2H8]-1 in three steps in 72% overall yield, while [13C6]phenol was used to prepare [13C6]-2 in four steps in 18% overall yield.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.30
自引率
0.00%
发文量
57
审稿时长
1 months
期刊介绍: The Journal of Labelled Compounds and Radiopharmaceuticals publishes all aspects of research dealing with labeled compound preparation and applications of these compounds. This includes tracer methods used in medical, pharmacological, biological, biochemical and chemical research in vitro and in vivo. The Journal of Labelled Compounds and Radiopharmaceuticals devotes particular attention to biomedical research, diagnostic and therapeutic applications of radiopharmaceuticals, covering all stages of development from basic metabolic research and technological development to preclinical and clinical studies based on physically and chemically well characterized molecular structures, coordination compounds and nano-particles.
期刊最新文献
Issue Information Preliminary Research of Radiolabeled Atezolizumab for the Noninvasive Evaluation of TNBC PD-L1 Expression In Vivo Issue Information Abstracts From the 29th International Isotope Society UK Meeting 17th November 2023 Lead-212/Bismuth-212 In Vivo Generator Based on Ultrasmall Silver Telluride Nanoparticles
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1